Bifidobacterium bacteria engineered to produce thymosin alpha-1 significantly boosted T cell numbers and immune function in mice when given orally, offering a potential alternative to injectable thymosin therapy.
Oral probiotic → systemic T cell boostMice fed engineered Bifidobacterium producing thymosin alpha-1 showed significantly increased CD4+ and CD8+ T cells in blood, spleen, and thymus compared to controls
What the researchers found
Researchers engineered Bifidobacterium longum bacteria to produce human thymosin alpha-1 (Tα1), then fed these bacteria to mice orally every other day for two weeks. Compared to control bacteria, the Tα1-producing bacteria significantly increased CD3+CD4+ and CD3+CD8+ T cells in the blood, spleen, and thymus, and boosted CD4+CD8+ cells in the thymus and spleen.
The immune-stimulating cytokines IFN-γ and IL-12 were significantly elevated in serum, while TNF-α and IL-4 were unchanged — indicating selective activation of the Th1 (cellular immunity) pathway. After three months of treatment, the mice showed thymic hyperplasia (enlarged thymus) and lymph node enlargement, confirming sustained immune organ growth from oral delivery.
Why it matters
Thymosin alpha-1 is an established immune-boosting peptide used clinically to treat immune deficiency and as an adjunct in hepatitis B and cancer therapy — but it must be given by injection. Converting it to an oral medication delivered by a probiotic bacterium could dramatically improve patient compliance and reduce side effects. This proof-of-concept in mice shows that a living bacterial delivery system can successfully produce and release a therapeutic peptide in the gut, where it stimulates systemic immune responses.
The numbers in context
Oral dosing every other day for 2 weeks · significant increases in CD4+ and CD8+ T cells · IFN-γ and IL-12 elevated · TNF-α and IL-4 unchanged · thymic hyperplasia and lymph node enlargement at 3 months · 0.2% L-arabinose induction
How the study worked
The researchers cloned the human thymosin alpha-1 gene into Bifidobacterium longum using an arabinose-inducible expression system. BALB/c mice received oral doses of the engineered bacteria (pre-induced with 0.2% L-arabinose) every other day for two weeks. Controls received bacteria transformed with an empty vector or normal saline. T cell populations were measured by flow cytometry in blood, spleen, and thymus. Serum cytokines (IFN-γ, IL-12, TNF-α, IL-4) were quantified. Long-term effects on thymus and lymph node morphology were assessed after three months.
Who was studied
BALB/c mice treated orally with engineered Bifidobacterium longum
What this study cannot tell us
This is a mouse study with no human data. The long-term safety of oral genetically modified bacteria is not well characterized. The thymic hyperplasia and lymph node enlargement observed at three months could potentially be concerning if they represent immune over-stimulation. The study does not quantify how much Tα1 actually reaches systemic circulation, and the mechanism of absorption from the gut is not fully characterized. Regulatory hurdles for genetically modified organisms as drug delivery vehicles are substantial.
How to read the evidence
This study is graded as preliminary because it was conducted entirely in mice. While the immune-boosting effects were consistent and multi-organ, no human testing has been performed, and the concept of using genetically modified bacteria as oral peptide delivery vehicles remains early-stage.
When this study was published
Published in 2013, this is an older study. The concept of engineered probiotic drug delivery has advanced significantly since then, but the specific Tα1-Bifidobacterium combination does not appear to have progressed to human trials.
The bigger picture
Using engineered bacteria as living drug factories is an exciting frontier in drug delivery. Bifidobacterium is particularly attractive because it's a normal inhabitant of the human gut and is already used in probiotics. If this approach works for thymosin alpha-1, it could be applied to other therapeutic peptides that currently require injection — potentially transforming how immune-modulating peptide therapies are administered. The concept bridges the worlds of synthetic biology, probiotics, and peptide therapeutics.
Questions still open
- Could this probiotic delivery system be adapted for other therapeutic peptides that currently require injection?
- Is the thymic hyperplasia observed at three months a beneficial effect or a sign of immune over-stimulation that could be harmful long-term?
- Would this engineered probiotic approach survive the human digestive system and produce enough thymosin alpha-1 to be clinically effective?
Common questions
What is thymosin alpha-1 and what is it used for?
How does a probiotic bacterium deliver a peptide drug?
Read the original research
Thymosin alpha-1-transformed Bifidobacterium promotes T cell proliferation and maturation in mice by oral administration.
International immunopharmacology, 15(3), 646-53
Citation
Shao, Congwen; Tian, Guojun; Huang, Yuanjian; Liang, Wenying; Zheng, Hang; Wei, Jiannan; Wei, Cheng; Yang, Cuilan; Wang, Hong; Zeng, Weisen. (2013). Thymosin alpha-1-transformed Bifidobacterium promotes T cell proliferation and maturation in mice by oral administration.. International immunopharmacology, 15(3), 646-53. https://doi.org/10.1016/j.intimp.2012.12.031